The clinico-molecular approaches for detection of human papillomavirus

[1]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[2]  R. Tripathi,et al.  Novel MicroRNA signatures in HPV-mediated cervical carcinogenesis in Indian women , 2016, Tumor Biology.

[3]  C. Pérez-Plasencia,et al.  Utility of MicroRNAs and siRNAs in Cervical Carcinogenesis , 2015, BioMed research international.

[4]  Vilas D. Nasare,et al.  Perception of Human Papillomavirus Infection, Cervical Cancer and HPV Vaccination in North Indian Population , 2014, PloS one.

[5]  R. Tripathi,et al.  Clinical Impact of De-Regulated Notch-1 and Notch-3 in the Development and Progression of HPV-Associated Different Histological Subtypes of Precancerous and Cancerous Lesions of Human Uterine Cervix , 2014, PloS one.

[6]  Min Liu,et al.  MicroRNA-10a targets CHL1 and promotes cell growth, migration and invasion in human cervical cancer cells. , 2012, Cancer letters.

[7]  B. Das,et al.  Human papillomavirus infection among young adolescents in India: Impact of vaccination , 2012, Journal of medical virology.

[8]  T. Onon.  History of human papillomavirus, warts and cancer: what do we know today? , 2011, Best practice & research. Clinical obstetrics & gynaecology.

[9]  D. Ma,et al.  Progressive miRNA expression profiles in cervical carcinogenesis and identification of HPV‐related target genes for miR‐29 , 2011, The Journal of pathology.

[10]  R. Gasparini,et al.  Cervical cancer: from Hippocrates through Rigoni-Stern to zur Hausen. , 2009, Vaccine.

[11]  B. Das,et al.  Prospects and prejudices of human papillomavirus vaccines in India. , 2008, Vaccine.

[12]  J. Minna,et al.  Silencing of HPV 18 Oncoproteins With RNA Interference Causes Growth Inhibition of Cervical Cancer Cells , 2007, Reproductive Sciences.

[13]  P. Maisonneuve,et al.  Carcinoma of the cervix uteri. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. , 2006, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[14]  S. Hietanen,et al.  Chemotherapy Compounds in Cervical Cancer Cells Primed by Reconstitution of p53 Function after Short Interfering RNA-Mediated Degradation of Human Papillomavirus 18 E6 mRNA: Opposite Effect of siRNA in Combination with Different Drugss⃞ , 2005, Molecular Pharmacology.

[15]  Thomas C Wright,et al.  The 2001 Bethesda System terminology. , 2003, American family physician.

[16]  Eileen M. Burd,et al.  Human Papillomavirus and Cervical Cancer , 1988, The Lancet.

[17]  J. Milner,et al.  Selective silencing of viral gene expression in HPV-positive human cervical carcinoma cells treated with siRNA, a primer of RNA interference , 2002, Oncogene.

[18]  H. zur Hausen.  Papillomaviruses and cancer: from basic studies to clinical application , 2002, Nature reviews. Cancer.

[19]  Jeffrey S. Tobias,et al.  Cancer and Its Management , 1995 .

[20]  H. zur Hausen.  Viruses in human cancers. , 1991, Science.

[21]  E. J. Dennis,et al.  The possible role of smegma in carcinoma of the cervix. , 1958, American journal of obstetrics and gynecology.

[22]  J. T. Syverton,et al.  THE CULTIVATION OF THE VIRUS OF ST. LOUIS ENCEPHALITIS. , 1935, Science.